

Supplementary table S1. Molecular characteristics of EGFR mutations, n=13

	Total group (n=415)	CRTL (n=222)	COMB (n=193)	p-value
EGFR mutation				
p.Leu747_Thr751delLeuArgGluAlaThrinsPro*, n (%)	1 (0.2)	-	1 (0.5) ins, del	-
p.Leu747_Pro753delinsSer*, n (%)	1 (0.2)	-	1 (0.5) ins, del	-
p.Asn771_Asn771delAsninsGlyThr**, n (%)	1 (0.2)	1 (0.5) del	-	-
p.Glu746_Ala750delGluLeuAr ¹ , n (%)	1 (0.2)	1 (0.5) del, sens	-	-
p.Glu746_Ala750delGluLeuArgGluAla ¹ , n (%)	1 (0.2)	-	1 (0.5) del, sens	-
p.Leu858Arg ¹ , n (%)	6 (1.4)	3 (1.4) point, sens	3 (1.6) point, sens	0.86
p.HisdupHis*, n (%)	1 (0.2)	1 (0.5) dupl	-	-
p.Ser768_Asp770dupSerValAsp**, n (%)	1 (0.2)	-	1 (0.5) dup	-
Total, n (%)	13 (3.1)	6 (2.7)	7 (3.6)	0.50
EGFR insertion mutations, n (%)	2 (0.5)	-	2 (1.0)	-
EGFR deletion mutations, n (%)	5 (1.2)	2 (0.9)	3 (1.6)	0.54
EGFR point mutations, n (%)	6 (1.4)	3 (1.4)	3 (1.6)	0.86
EGFR duplication mutation, n (%)	2 (0.5)	1 (0.5)	1 (0.5)	0.92
EGFR Mutation sensitive against TKI, n (%)	8 (1.9)	4 (1.8)	4 (2.1)	0.84

Molecular characteristics and types of EGFR-mutations; ins, insertion mutation; del, deletion mutation; point, point mutation; dupl, duplication mutation; sens, sensitive against tyrosine kinase inhibitors; TKIs, tyrosine kinase inhibitors; *no sensitivity against TKIs; **no sensitivity against TKIs of 1st, 2nd or 3rd generation; ***no information on TKI-sensitivity; ¹ sensitive against TKI

Supplementary table S2. Multivariate cox proportional analysis in advanced or metastasized NSCLC patients treated with PD-1/PD-L1 inhibitors

	aHR	(95% CI)	P-Value
VA vs. non-VA	0.451	0.282 - 0.720	0.0008***
Age	0.999	0.973 - 1.025	0.91
Gender, female vs. male	0.625	0.372 - 1.052	0.08.
BMI 25 – 29.9 kg/m ² vs. <25 kg/m ²	0.614	0.369 - 1.022	0.06.
BMI ≥30 kg/m ² vs. <25 kg/m ²	0.273	0.115 - 0.648	0.003 **
ECOG status	1.399	1.126 - 1.738	0.002 **
Smoker, current/past vs. never	1.342	0.622 - 2.895	0.45
Comorbidities, yes vs. no	0.418	0.246 - 0.710	0.0013 **
Surgery, yes vs. non	0.792	0.369 - 1.702	0.55
Stage IV UICC vs. stage III UICC	0.723	0.312 - 1.676	0.45
Brain radiation vs. no brain radiation	1.302	0.704 - 2.408	0.40
PD-L1 TPS 1-10%	0.766	0.418 - 1.403	0.38
PD-L1 TPS 11-20%	1.102	0.394 - 3.085	0.85
PD-L1 TPS 21-30%	0.822	0.341 - 1.979	0.66
PD-L1 TPS 31-40%	0.618	0.180 - 2.123	0.44
PD-L1 TPS 41-50%	6.001	1.301 - 27.684	0.022*
PD-L1 TPS 51-60%	0.570	0.212 - 1.536	0.27

PD-L1 TPS 61-70%	0.374	0.115 - 1.217	0.10
PD-L1 TPS 71-80%	0.491	0.145 - 1.668	0.25
PD-L1 TPS 81-90%	0.609	0.270 - 1.372	0.23
PD-L1 TPS 91-100%	0.718	0.149 - 3.448	0.68
EGFR, positive	1.068	0.477 - 2.391	0.87

*Adjusted multivariate cox proportional analysis of association of add-on VA with adjusted hazard of death in advanced or metastasized NSCLC patients treated with PD-1/PD-L1 inhibitors, n=162; aHR, adjusted hazard ratio; VA, Viscum album L.; BMI, body mass index; PD-L1, programmed death-ligand 1; TPS, tumour proportion score; EGFR, epidermal growth factor receptor *, p-value <0.05; **, p-value <0.01; ***, p-value <0.001*